Recent research has uncovered promising results, such as enhanced overall survival and/or progression-free survival, among patients with advanced GC expressing the PD-L1 marker who received treatment with anti-PD-1/ PD-L1 inhibitors, a class of immune checkpoint inhibitors (ICIs) (12,13). The gene discussed is CD274; the disease is gastric cancer.